A dermatology-focused branch of Roivant Sciences, Dermavant Sciences has publicized today how it has begun an association and license contract with Japan Tobacco Inc. for the exclusive right to progress, register, and commercialize tapinarof in Japan to treat dermatological ailments and conditions, such as psoriasis and atopic dermatitis. Together with this contract, Japan Tobacco has also begun an exclusive license contract with its sub-branch, Torii Pharmaceutical Co., Ltd., to join to advance and market tapinarof in Japan.
A once-daily topical therapeutic aryl hydrocarbon receptor modulating agent, tapinarof is being advanced by Dermavant Sciences to successfully treat psoriasis and atopic dermatitis. Up till now, more than 1,400 subjects have taken part in 12 clinical trials conducted for tapinarof. It is presently in Phase 3 trials for psoriasis in the United States. For psoriasis and atopic dermatitis both, tapinarof has previously showcased clinically significant and statistically important outcomes in Phase 2 trials. If it receives favorable outcomes in Phase 3, Dermavant Sciences hopes to file a New Drug Application for tapinarof topical cream to treat plaque psoriasis with the FDA next year.
According to the terms of the contract, Dermavant Sciences will be given a payment of $60 million as well as about $53 million following the completion of certain set milestones. Additionally, Dermavant Sciences will have the right to gain royalties through sales of tapinarof.
The CEO of Dermavant Sciences, Todd Zavodnick stated how psoriasis and atopic dermatitis impact millions of individuals around the globe. In Japan alone, they affect about 13 million people. He stated that following the promising outcomes of Phase 2b researches carried out in Japan and North America for tapinarof, they are pleased to join forces with Japan Tobacco and Torri, 2 renowned and esteemed forerunners in the industry.